Harvard's faith in Evotec pays off with Janssen diabetes deal
This article was originally published in Scrip
Harvard University's faith in German drug discovery services company Evotec has paid off. Just over a year ago, the top US academic powerhouse turned to Evotec to add value to its early-stage diabetes assets, in a bid to increase the chance of development success.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.